Private company
Soleus Private Equity Fund III, L.P.
Private equity fund that raised $218 million in 2022 (SEC Form D). Summary from the record
Last updated Oct 21, 2026.
Overview
Corporate structure
Soleus Private Equity Fund III, L.P. sits at the top of its group. 13 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
- Soleus Private Equity Fund III, L.P. DE
- Aprea Therapeutics, Inc. Stake · Doylestown, Pennsylvania
- CalciMedica, Inc. Stake · La Jolla, California
- Harpoon Therapeutics, Inc. Stake · South San Francisco, California, United States
- IMMUNIC, INC. Stake · Wilmington, Delaware, United States
- Inhibikase Therapeutics, Inc. Stake · Atlanta, Georgia, United States
- InspireMD, Inc. Stake · Boston, Massachusetts, United States
- Invivyd, Inc. Stake · New Haven, Connecticut
- Jasper Therapeutics, Inc. Stake · Redwood City, California
- Mereo BioPharma Group plc Stake · London, United Kingdom
- Nuvectis Pharma, Inc. Stake · Fort Lee, New Jersey
- Prelude Therapeutics Inc Stake · Wilmington, Delaware
- Verastem Oncology Stake · Needham
Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (12 companies). Each entity in the chart links to its source.
Leadership
Named in SEC Form D filings
People the company listed in its private-offering notices.
- Mr. Levy is the Chief Executive Officer and Chief Investment Officer of the General Partner of the Issuer and the Chief Investment Officer of the Management Company of the Issuer.Guy Levy named Feb 27, 20242
- Mr. Musumeci is the Chief Operating Officer of the General Partner of the Issuer.Steven J. Musumeci named Feb 27, 20242
Filings
2 filings to the SEC since October 2021: 2 private raises. The latest 2:
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Stakes it holds
Soleus Private Equity Fund III, L.P. has told the SEC it owns more than 5% of 12 companies, latest first (Schedules 13D and 13G).
- Nuvectis Pharma, Inc.SCHEDULE 13G Aug 6, 20263
- Prelude Therapeutics IncSCHEDULE 13G Jul 8, 20264
- CalciMedica, Inc.SCHEDULE 13G/A Nov 14, 2024 to May 8, 20265
- Aprea Therapeutics, Inc.SCHEDULE 13G Apr 1, 20266
- Invivyd, Inc.SCHEDULE 13G/A Oct 14, 2025 to Feb 12, 20267
- IMMUNIC, INC.SCHEDULE 13G/A Jan 10, 2024 to Nov 7, 20258
- Verastem OncologySCHEDULE 13G/A Nov 14, 2024 to May 2, 20259
- Jasper Therapeutics, Inc.SC 13G/A Nov 14, 202410
- Mereo BioPharma Group plcSC 13G/A Jul 26, 2023 to Nov 14, 202411
- Inhibikase Therapeutics, Inc.SC 13G Oct 28, 202412
- Harpoon Therapeutics, Inc.SC 13G/A Oct 26, 2023 to Feb 6, 202413
- InspireMD, Inc.SC 13G May 24, 202314
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $218.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2022 | $218.0M | $218.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14